Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
Keratoconjunctivitis sicca (KCS) is a prevalent and often vision-threatening condition in dogs. In several reports, 2% cyclosporine (cyclosporin A, CsA) was described as effective in modulating the clinical signs of KCS. This study was designed to compare the efficacy of 1% CsA vs a placebo, using a randomized double-blind clinical trial. Topical administration of 1% CsA significantly improved Schirmer wetting values and subjective markers of corneal health as compared with the placebo. In the dogs treated with topical administration of 1% CsA, the clinical signs of KCS were improved in 81.8% of cases.
Olivero
D K
DK
Department of Companion Animal and Special Species Medicine, College of Veterinary Medicine, North Carolina State University, Raleigh 27606.
Davidson
M G
MG
English
R V
RV
Nasisse
M P
MP
Jamieson
V E
VE
Gerig
T M
TM
D000287:Administration, Topical; D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004311:Double-Blind Method; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy / Q000662:veterinary*; D009883:Ophthalmic Solutions
D009883:Ophthalmic Solutions; D016572:Cyclosporine